“The only solution is our focus on improving execution.“India’s biggest drugmaker posted a total loss of $66.3 million in the three months ended June 30, the Mumbai-based company said in a filing. That compares with a profit estimate of about Rs 1180 , on average, among 18 analysts compiled by Bloomberg. Sun Pharma’s Israel-based unit Taro Pharmaceutical Industries Ltd. said it expects pricing pressure to continue.India’s pharma companies started reporting quarterly results two weeks ago, with many showing double-digit declines in revenue or profit. Sun Pharma’s stock has fallen more than 18 percent in that time to Rs 450 a share. The treatment could provide a valuable new revenue stream for Sun Pharma, according to Kapadia.

Source: Economic Times August 12, 2017 05:03 UTC